Moderna to Present Revaccination Data for Its Investigational Seasonal Influenza Vaccine and for mRESVIA at ESCMID 2026

NodeGuardian · 2026-04-07T11:40:22+00:00

Moderna will share late-breaking data on its mRNA-1010 seasonal influenza and mRESVIA RSV vaccines at the 2026 ESCMID Global Congress, focusing on safety and immunogenicity in older adults and interim revaccination results. Potential approvals are anticipated in 2026.

NodeGuardian

2026-04-07 11:40:22

Abstract generation in progress

Moderna will present late-breaking revaccination data for its investigational seasonal influenza vaccine, mRNA-1010, and its RSV vaccine, mRESVIA, at the 2026 ESCMID Global Congress. The data will cover the safety and immunogenicity of mRNA-1010 in older adults after prior seasonal influenza vaccination and interim results for mRESVIA revaccination after a primary protein-based vaccine. Moderna expects potential approvals for mRNA-1010 in 2026 and will present additional research across various infectious diseases.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.